NK3R Agonist

Senktide is a potent, selective agonist of the neuromedin K3 (NK3) receptor (EC₅₀=0.5-3 nM). Senktide less potently agonizes the NK1 receptor (EC₅₀=35 µM). Senktide is promising for research of neurological disease.

Neurokinin B TFA is a tachykinin family peptide that preferentially binds to and activates NK3R over other tachykinin receptors. Neurokinin B TFA preferentially binds to the substance P receptor (SP-N receptor) and mediates acetylcholine release from cholinergic neurons. Neurokinin B TFA regulates the pulsatile release of Kisspeptin and GnRH, stimulates or inhibits the secretion of luteinizing hormone (HY-P2293), regulates reproductive function via metabolic signals, and drives the onset of puberty. Neurokinin B TFA exerts vasoactive effects and induces contraction of isolated guinea pig ileum. Neurokinin B TFA can be used in studies related to hypogonadotropic hypogonadism.

Neurokinin B is a tachykinin family peptide that preferentially binds to and activates NK3R over other tachykinin receptors. Neurokinin B preferentially binds to the substance P receptor (SP-N receptor) and mediates acetylcholine release from cholinergic neurons. Neurokinin B regulates the pulsatile release of Kisspeptin and GnRH, stimulates or inhibits the secretion of luteinizing hormone (HY-P2293), regulates reproductive function via metabolic signals, and drives the onset of puberty. Neurokinin B exerts vasoactive effects and induces contraction of isolated guinea pig ileum. Neurokinin B can be used in studies related to hypogonadotropic hypogonadism.

Hemokinin 1, human is a selective tachykinin neurokinin 1 (NK1) receptor full agonist. Hemokinin 1, human is a full agonist at NK2 and NK3 receptor. Hemokinin 1, human can produces an opioid-independent analgesia.

Hemokinin 1, human TFA is a selective tachykinin neurokinin 1 (NK1) receptor full agonist. Hemokinin 1, human TFA is a full agonist at NK2 and NK3 receptor. Hemokinin 1, human TFA can produces an opioid-independent analgesia.

Senktide TFA is a potent, selective agonist of the neuromedin K3 (NK3) receptor (EC₅₀=0.5-3 nM). Senktide TFA less potently agonizes the NK1 receptor (EC₅₀=35 µM). Senktide TFA is promising for research of neurological disease.

[Lys5,Tyr6,mLeu9,Nle10]-Neurokinin A (4-10) (ID 305) is a selective NK2R agonist with an EC₅₀ of 3.7  nM for hNK2R. [Lys5,Tyr6,mLeu9,Nle10]-Neurokinin A (4-10) significantly inhibits weight loss in diet-induced obese (DIO) mice model and improves Loperamide (HY-156131)-induced dysfunctional voiding in wild-type mice. [Lys5,Tyr6,mLeu9,Nle10]-Neurokinin A (4-10) can be used for neurokinin receptor mediated disorders, such as obesity, insulin resistance and type 2 diabetes research.

[Asp5,6,Me-Phe8] Substance P (5-11) is a tachykinin NK-3 receptor agonist. [Asp5,6,Me-Phe8] Substance P (5-11) reduces alcohol intake in genetically selected alcohol-preferring rats.